DelveInsight’s “Metastatic Urothelial Carcinoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Urothelial Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Metastatic Urothelial Carcinoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metastatic Urothelial Carcinoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Metastatic Urothelial Carcinoma: An Overview
Urothelial Carcinoma starts when cells that make up the urinary bladder become cancerous. Bladder neoplasms can arise from any of the four bladder wall layers. They are broadly classified as either epithelial or non-epithelial (mesenchymal), with over 95% being epithelial. Epithelial tumors with differentiation toward normal urothelium are urothelial/ urinary carcinoma (UC). Other types of bladder neoplasms, namely, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and sarcoma account for 2–5% of bladder neoplasms. The majority of UC occurs in males with approximately two to threefold greater incidence as compared to females. UC is the invasion of the basement membrane or lamina propria by neoplastic cells of urothelial origin.
The main causative agents of upper tract UC and urinary bladder cancer include cigarette smoking and work-related exposure, while other factors are more specific to the carcinogenesis of upper tract UC (i.e., Balkan endemic nephropathy).
From a clinical point of view, urinary bladder cancers are classified as non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), because the invasion of the muscle layer is the major determinant of carrying out a cystectomy. The 5-year relative survival rate for patients with UBC ranges from 97% (stage I) to 22% (stage IV). The World Health Organization classifies bladder cancers based on the type of tumor from low-grade (grade I and II) to high-grade (grade III). The WHO has substituted the old term provisional cell carcinoma with urothelial carcinoma. Invasion is referred to as ‘microinvasion’ when the complexity of invasion is 2 mm or less.
Metastatic Urothelial Carcinoma Market Key Facts
-
As per the National Cancer Institute, a high increase in the number of cases of UC with an estimated number of 80,470 newly diagnosed cases and 17,670 deaths was expected in 2019 in the United States.
-
A review paper published by Clinton et al. titled “Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer”, stated that approximately 75% of newly diagnosed bladder cancer cases present as non-muscle invasive bladder cancer (NMIBC) out of which 50–70% recur and 10–20% progress to muscle-invasive bladder cancer (MIBC).
Metastatic Urothelial Carcinoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metastatic Urothelial Carcinoma pipeline therapies. It also thoroughly assesses the Metastatic Urothelial Carcinoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Metastatic Urothelial Carcinoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Metastatic Urothelial Carcinoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Metastatic Urothelial Carcinoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Metastatic Urothelial Carcinoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Metastatic Urothelial Carcinoma Epidemiology, Segmented as –
-
Diagnosed Incident Population of Urothelial Carcinoma in the 7MM [2019–2032]
-
Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the 7MM [2019–2032]
-
Severity-specific Diagnosed Incident Population of Urothelial Carcinoma in the 7MM [2019–2032]
-
Age-specific Diagnosed Incident Population of Urothelial Carcinoma in the 7MM [2019–2032]
-
Gender-specific Diagnosed Incident Population of Urothelial Carcinoma in the 7MM [2019–2032]
-
Tumor (T) stage-specific Diagnosed Incident Population of Urothelial Carcinoma in the 7MM [2019–2032]
-
Metastatic stage-specific Diagnosed Incident Population of Urothelial Carcinoma in the 7MM [2019–2032]
Metastatic Urothelial Carcinoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Metastatic Urothelial Carcinoma market or expected to be launched during the study period. The analysis covers the Metastatic Urothelial Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Metastatic Urothelial Carcinoma drugs based on their sale and market share.
The report also covers the Metastatic Urothelial Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Metastatic Urothelial Carcinoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Metastatic Urothelial Carcinoma Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/metastatic-urothelial-carcinoma-market
Metastatic Urothelial Carcinoma Therapeutics Analysis
UC, also known as transitional cell carcinoma (TCC), is characterized by cancer beginning in the urothelial cells lining the bladder, it is one of the most common forms of bladder cancer (BC). Treatment for metastatic form of Urothelial Carcinoma (UC) can be employed in different classes of chemotherapy, immunotherapy, radiation therapy, target-specific therapy, and surgical treatment. Metastatic Urothelial Carcinoma has shown poor survival when treated with chemotherapy; however, due to the advancements in the treatment of new immunotherapies, more alternatives are available.
Chemotherapy majorly forms the first line of treatment, mainly comprising platinum-based products. Cisplatin-based chemotherapy is a chief product in the list of chemotherapeutics. The commonly used cisplatin regimens include MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) or GC (gemcitabine and cisplatin). Cisplatin is followed by Carboplatin for therapeutic regimens, such as M-CAVI (methotrexate, carboplatin, and vinblastine). A few nonplatinum regimens include gemcitabine with a taxane (either paclitaxel or docetaxel) rather than platinum. Single-agent chemotherapy also holds importance in the treatment routine, including Gemcitabine, Vinflunine, and Ifosfamide.
The major class of treatment also comprises Immunotherapy, which helps the patient’s own immune system to recognize and destroy cancer cells. Developments in this domain have led to the development of immune checkpoint inhibitors (ICIs) targeting the programmed death (PD-1/PDL-1) pathway. Immunotherapy is used in platinum-ineligible or refractory cases. The market holds Atezolizumab (Tecentriq), Pembrolizumab (Keytruda), Nivolumab (Opdivo), Durvalumab (Imfinzi), and Avelumab (Bavencio) as approved products targeting PD-1/PDL-1 pathway.
Several major pharma and biotech giants are developing therapies for Metastatic Urothelial Carcinoma. Currently, PharmaMar is leading the therapeutics market with its Metastatic Urothelial Carcinoma drug candidates in the most advanced stage of clinical development.
Metastatic Urothelial Carcinoma Companies Actively Working in the Therapeutics Market Include
-
PharmaMar
-
Ectin Research AG
-
Exelixis
-
Eli Lilly and Company
-
Merck Sharp & Dohme LLC
-
Astellas Pharma Inc
-
Seagen Inc.
-
Shanghai Miracogen Inc.
-
Advaxis, Inc.
And Many Others
Emerging and Marketed Metastatic Urothelial Carcinoma Therapies Covered in the Report Include:
-
MFA 370: Ectin Research AG
-
XL 092: Exelixis
-
Lurbinectedin: PharmaMar
-
Ramucirumab: Eli Lilly
-
Infigratinib: QED Therapeutics
-
Rogaratinib: Bayer
- Pemigatinib: Incyte Corporation
-
Sacituzumab govitecan: Immunomedics
-
NKTR-214: Nektar Therapeutics/Bristol-Myers Squibb
-
RX-3117: Rexahn Pharmaceuticals
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/metastatic-urothelial-carcinoma-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Urothelial Carcinoma Competitive Intelligence Analysis
4. Metastatic Urothelial Carcinoma Market Overview at a Glance
5. Metastatic Urothelial Carcinoma Disease Background and Overview
6. Metastatic Urothelial Carcinoma Patient Journey
7. Metastatic Urothelial Carcinoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Metastatic Urothelial Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Urothelial Carcinoma Unmet Needs
10. Key Endpoints of Metastatic Urothelial Carcinoma Treatment
11. Metastatic Urothelial Carcinoma Marketed Therapies
12. Metastatic Urothelial Carcinoma Emerging Drugs and Latest Therapeutic Advances
13. Metastatic Urothelial Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Urothelial Carcinoma Market Outlook (In US, EU5, and Japan)
16. Metastatic Urothelial Carcinoma Companies Active in the Market
17. Metastatic Urothelial Carcinoma Access and Reimbursement Overview
18. KOL Views on the Metastatic Urothelial Carcinoma Market
19. Metastatic Urothelial Carcinoma Market Drivers
20. Metastatic Urothelial Carcinoma Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/metastatic-urothelial-carcinoma-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
The global Hernia Repair Devices Market was valued at USD 4.00 billion in 2021, growing at a CAGR of 5.08% during the forecast period from 2023 to 2028 to reach USD 5.38 billion by 2028. The rise in demand for Hernia Repair Devices is primarily attributed to the rising incidence of hernia, growing surgeries for hernia treatment, technological advancement in the product portfolio, and favorable reimbursement scenarios, among others. Some of the Hernia Repair Devices companies actively operating in the global market include Medtronic, Johnson & Johnson, Inc., B. Braun Melsungen AG, Cook, Gem Srl, PRIMEQUAL SA, Becton, Dickinson and Company, Deep Blue Medical Inc., Meril Life Sciences Pvt. Ltd., Changzhou Medical Equipment General Factory Co., Ltd., Sinolinks Medical Innovation, Cousin Surgery, Aspide Medical S.A.S., among others.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research